Europe Contraceptives Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 7.15 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Contraceptives Market Analysis
The European contraceptives market is expected to witness a CAGR of 7.15% during the forecast period.
COVID-19 has significantly impacted the European contraceptive market due to the barriers to accessing contraceptives due to supply chain disruption and lockdown restrictions. For instance, the European Parliamentary Forum for Sexual and Reproductive Rights report published in September 2021 stated that 12.5% of Spanish women quit using the hormonal contraceptive pill and discontinued the drug because getting a prescription was difficult during COVID-19 due to the disruption in the healthcare services. This has impacted the market growth leading to a decline in sales of contraceptives in Europe. However, in the current scenario, with the ease of restrictions and availability of all the healthcare services, the demand for contraceptives may grow in European countries, which is expected to drive the growth of the studied market over the forecast period.
The increasing awareness about sexually transmitted diseases (STDs), the rising rate of unintended pregnancies, and increased government initiatives are the major factors driving the market growth. For instance, in November 2021, a report published by European Centre for Disease Prevention and Control stated that the sex between men and women is the second most commonly reported mode of transmission in the European Union, accounting for 29.7% (4,445) of all HIV diagnoses. The highest proportions of these were observed in France, 53.0%. Thus, such instances indicate that the demand for contraceptive devices may increase. Thereby considerable market growth is anticipated over the forecast period.
Moreover, the increasing cases of unintended pregnancies leading to abortions also increase the demand for contraceptives. For instance, an article published by the Journal of Health Monitoring in June 2022 reported that 94,596 abortions were recorded in Germany in 2021. The highest number of abortions was recorded in women aged between 30 and 24. Thus, an increased number of abortions due to unintended pregnancy is driving the demand for contraceptives in the regions, fueling the studied market's growth.
Furthermore, rising approvals from the European Union on oral contraceptives will drive market growth over the forecast period. For instance, in May 2021, European Commission accepted the registration application for the novel combined oral contraceptive Estelle developed by Mithra, a company dedicated to Women's Health. Such approvals will lead to increased adoption of oral contraceptives in Europe due to the rise in the availability of contraceptives in the market.
Thus, due to the increasing prevalence of sexually transmitted diseases (STDs), the growing rate of unintended pregnancies, the increasing demand for modern contraceptive methods, and rising approvals from the European Union for the use of contraceptives, the studied market is expected to witness significant growth over the forecast period. However, factors such as the side effects of contraception and sociocultural issues associated with contraception are expected to hinder market growth.
Europe Contraceptives Market Trends
Condoms are Expected to Witness Significant Growth in the Market Over the Forecast Period
Condom use has significantly increased in adolescents due to easy availability and convenience. Furthermore, adequate protection from sexually transmitted infections and demand from the young population to enhance their sexual experience is expected to aid the product demand.
The rising initiatives from European countries on contraception for their residents are expected to drive the growth of this segment in Europe. For instance, in December 2022, an announcement was made by the President of France that stated young people in France would be able to get condoms free of charge from 2023 to reduce the spread of sexually transmitted diseases (STDs). The France health authorities also reported that the rate of STDs increased by about 30% in 2021 in France due to government initiatives and further decreased by the government enabling free condoms initiatives for young people in the country.
Moreover, according to the study published in the Journal of Scientific Research, in January 2022, in the United Kingdom, CSD500, a novel condom, appears to hold significant potential for its role as a condom that could improve men's and women's sexual pleasure. Thus, the availability of such condoms may increase the use of such condoms. Such studies are expected to drive this segment's growth further. In addition, the availability of different variants under the brands with high-quality standards, cost-effectiveness, and easy access from supermarkets, drug stores, and e-commerce platforms paved the way for this verticle.
Furthermore, the increasing use cases of STDs reported in European countries is also increasing the demand for condoms, thus driving this segment's growth. For instance, an article published by NCBI in May 2022 reported that a study conducted in France stated that syphilis prevalence and incidence were relatively high in France, especially among males who have sex with males with controlled HIV infection and pre-exposure prophylaxis users. The study also recommended that syphilis screening should be increased and behavioral risk reduction counseling among high-risk subjects should be conducted. Condoms are one of the essential requirements to lower the cases of sexually transmitted diseases; thus, increasing the chances of syphilis is driving the growth of this segment. Therefore, raising awareness among young adults about contraceptives and rising government initiatives are driving the development of this segment.
United Kingdom Expected to Witness Significant Growth in the Market Over the Forecast Period.
The United Kindom is expected to hold a significant share due to the rise in sexually transmitted diseases, initiatives taken by the key market players to launch new products, and the increasing number of unintended pregnancies. For instance, according to the Government of United Kingdom data published in November 2022, reported that 88.7 thousand HIV cases were reported in the United Kingdom in the year previous year, and this number is expected to increase to 91.4 thousand in the year 2021. The increasing HIV cases are constantly demanding for increasing use of contraceptives and thus driving the growth of the studied market.
Moreover, the increasing cases of unintended pregnancies leading to abortions drive the growth of the studied market in the country. For instance, in December 2021, statistics published by the United Kingdom government reported 214,256 abortions in England and Wales in 2021. In addition, the same source also said that 89% of abortions were performed in women under ten weeks in 2021 compared to 88% in the previous year. Thus, the rising number of abortions in the country is expected to increase the demand for contraceptive devices among the population, thereby propelling market growth.
Furthermore, in July 2021, HRA Pharma Consumer Healthcare company received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) for the launch of the first type of contraceptive pill that will be available to buy in the United Kingdom without a prescription following a pharmacist consultation, that make it easier for some women to access and therefore use. In addition, in July 2021, United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) also granted Maxwellia's Lovina, a contraceptive pill that can be sold over the counter without a prescription. These authorizations in the United Kingdom are anticipated to drive market growth in this region due to the rise in the adoption of contraceptives. Thus, due to growing STDs, unintended pregnancies leading to abortion, regulatory approvals in the country, and increasing awareness about contraceptives, the market studied are expected to witness significant growth in the United Kingdom.
Europe Contraceptives Industry Overview
The European contraceptive market is highly competitive and consists of several players. Some of the key market players in the European contraceptives market include Actavis PLC, Agile Therapeutics, ANI Pharmaceuticals Inc., Bayer Healthcare, Fuji Latex Co., Ltd, Johnson & Johnson Ltd, HRA Pharma, Pfizer, Teva Pharmaceuticals Ltd, the Female Health Company, among others.
Europe Contraceptives Market Leaders
-
Bayer AG
-
Pfizer Inc
-
The Female Health Company uk
-
Mithra Pharmaceuticals
-
Cooper Surgical, Inc
*Disclaimer: Major Players sorted in no particular order
Europe Contraceptives Market News
- In September 2022, Novo Nordisk launched an over-the-counter hormone replacement therapy drug in the United Kingdom.
- In July 2022, Organon entered into a research collaboration and exclusive license agreement with Denmark's Cirqle Biomedical for a novel investigational non-hormonal, on-demand contraceptive candidate.
Europe Contraceptives Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of STDs
- 4.2.2 Growing Rate of Unintended Pregnancies
- 4.2.3 Increasing Demand for Modern Contraceptive Methods and Rising Government Initiatives
-
4.3 Market Restraints
- 4.3.1 Side Effects of Using Contraception and Socio-cultural Issues Associated with Contraception
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product
- 5.1.1 Drugs
- 5.1.1.1 Oral Contraceptive Pills
- 5.1.1.2 Injectable Contraceptives
- 5.1.1.3 Topical Contraceptives
- 5.1.2 Devices
- 5.1.2.1 Condoms
- 5.1.2.2 Diaphragms
- 5.1.2.3 Contraceptive Sponges
- 5.1.2.4 Vaginal Rings
- 5.1.2.5 Subdermal Implants
- 5.1.2.6 Intra-Uterine Devices
- 5.1.2.7 Other Devices
-
5.2 By Gender
- 5.2.1 Male
- 5.2.2 Female
-
5.3 Geography
- 5.3.1 Germany
- 5.3.2 United Kingdom
- 5.3.3 France
- 5.3.4 Italy
- 5.3.5 Spain
- 5.3.6 Rest of Europe
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc
- 6.1.2 Bayer AG
- 6.1.3 Reckitt Benckiser Group PLC
- 6.1.4 Johnson & Johnson Ltd
- 6.1.5 HRA Pharma
- 6.1.6 Pfizer Inc
- 6.1.7 CooperSurgical Inc
- 6.1.8 The Female Health Company
- 6.1.9 Johnson & Johnson Ltd
- 6.1.10 Mithra Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityEurope Contraceptives Industry Segmentation
As per the scope of the report, contraception (birth control) prevents pregnancy by interfering with the usual process of ovulation, fertilization, and implantation. There are diverse kinds of birth control that act at different points in the procedure. In addition, barrier methods, such as condoms, are a form of contraception that helps protect against sexually transmitted infections (STIs) and pregnancy. The Europe Contraceptives Market is segmented by Product (Drugs (Oral Contraceptive Pills, Injectable Contraceptives, and Topical Contraceptives), Devices (Condoms, Diaphragms, Contraceptive Sponges, Vaginal Rings, Subdermal Implants, Intra-uterine Devices, and Other Devices), Gender (Male and Female), Geography (Germany, United Kingdom, France, Italy, Spain and Rest of Europe). The report offers the value (in USD million) for the above segments.
| By Product | Drugs | Oral Contraceptive Pills |
| Injectable Contraceptives | ||
| Topical Contraceptives | ||
| By Product | Devices | Condoms |
| Diaphragms | ||
| Contraceptive Sponges | ||
| Vaginal Rings | ||
| Subdermal Implants | ||
| Intra-Uterine Devices | ||
| Other Devices | ||
| By Gender | Male | |
| Female | ||
| Geography | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe |
Europe Contraceptives Market Research FAQs
What is the current Europe Contraceptives Market size?
The Europe Contraceptives Market is projected to register a CAGR of 7.15% during the forecast period (2024-2029)
Who are the key players in Europe Contraceptives Market?
Bayer AG, Pfizer Inc, The Female Health Company uk, Mithra Pharmaceuticals and Cooper Surgical, Inc are the major companies operating in the Europe Contraceptives Market.
What years does this Europe Contraceptives Market cover?
The report covers the Europe Contraceptives Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Contraceptives Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Contraceptives Industry Report
Statistics for the 2024 Europe Contraceptives market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Contraceptives analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
